Q-omics provides the consensus-scored UPK3A profile across patient tissues and cancer cell-line models. UPK3A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, UPK3A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, UPK3A RNA expression shows 15,063 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, THCA, and TGCT as cancer lineages where UPK3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UPK3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UPK3A survival associations across molecular data types. UPK3A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UPK3A RNA expression–survival associations across cancer types. High UPK3A expression shows unfavorable associations in LIHC, UCS and LAML, but favorable associations in HNSC, SKCM and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for UPK3A RNA expression.
This table summarizes UPK3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for UPK3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UPK3A shows lower tumor expression in THCA and HNSC and higher tumor expression in LUAD, LIHC, KIRC and STAD. The THCA box plot shows higher UPK3A RNA expression in normal versus tumor tissue (log2 FC = −3.585, t-test p < 0.001).
This table shows molecular features associated with UPK3A in patient tissues and cancer cell lines. In patient samples, UPK3A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UPK3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
